1 recruiting, 1 terminated. 1 Phase 1, 1 Phase 2, 1 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 1 | Terminated 1 |
| Phase 2 | 1 | Terminated 1 |
| Phase 4 | 1 | Recruiting 1 |
Follow Brett King: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Adaptive Optics OCT Evaluation of Rhopressa's Effects on the Retinal Ganglion Cells in Glaucoma Patients Netarsudil 0.02% Ophthalmic Solution [RHOPRESSA], Timolol Maleate 0.25% Ophthalmic Solution - Open Angle Glaucoma (OAG), Glaucoma | Phase 4 | Recruiting | Brett King | 13 | 2026-10-01 | 2026-10-28 |
| Study to Evaluate the Use of Palifermin to Treat Toxic Epidermal Necrolysis Palifermin - Toxic Epidermal Necrolysis, Stevens-Johnson Syndrome | Phase 1 / Phase 2 | Terminated | Brett King | 1 | 2010-10-01 | 2016-11-30 |
Glaucoma (1) · Glaucoma, Open-Angle (1) · Stevens-Johnson Syndrome (1)
Fibroblast Growth Factor 7 (1) · Ophthalmic Solutions (1) · Timolol (1) · netarsudil (1)
United States (2)